Today’s Price Action: Heron Therapeutics Inc’s Trend Down, Especially After Today’s 52 Week Low Hit

Today's Price Action: Heron Therapeutics Inc's Trend Down, Especially After Today's 52 Week Low Hit

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) hit a new 52-week low and has $13.66 target or 8.00% below today’s $14.85 share price. The 5 months bearish chart indicates high risk for the $572.35M company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $13.66 price target is reached, the company will be worth $45.79M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 107,749 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 23.02% since March 29, 2016 and is downtrending. It has underperformed by 26.49% the S&P500.

Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on November, 4. They expect $-1.11 EPS, down 76.19% or $0.48 from last year’s $-0.63 per share. After $-1.17 actual EPS reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.13% EPS growth.

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Out of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 11 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Monday, August 3 by Brean Capital. The rating was initiated by Lake Street with “Buy” on Thursday, December 10. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) has “Buy” rating given on Wednesday, October 26 by Aegis Capital. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, September 23 report. The rating was initiated by Bank of America with “Buy” on Wednesday, September 2. As per Wednesday, September 23, the company rating was maintained by Jefferies. Brean Capital maintained Heron Therapeutics Inc (NASDAQ:HRTX) on Monday, August 10 with “Buy” rating.

According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”

Another recent and important Heron Therapeutics Inc (NASDAQ:HRTX) news was published by Nasdaq.com which published an article titled: “Oversold Conditions For Heron Therapeutics” on October 03, 2016.

HRTX Company Profile

Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment